Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Spain,Italy,France,Switzerland,Poland,Germany,Sweden,Russian Federation,United Kingdom,Canada
nct
Update Il y a 5 ans
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer. Participants will be randomized to receive either SC Herceptin or IV Herceptin every 3 weeks for Cycles 1 to 4, followed by crossover to the other treatment administration for Cycles 5 to 8. For up to 10 additional cycles (for a total of 18 cycles), participants will receive IV or SC Herceptin every 3 weeks.
Country
Canada
,
Denmark
,
France
,
Germany
,
Italy
,
Poland
,
Russian Federation
,
Spain
,
Sweden
,
Switzerland
,
Turkey
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
Country
Austria
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Country
Australia
,
Austria
,
Belgium
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Country
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Mexico
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1